Multicenter, Randomized, Subject/Evaluator Blind, Active Control, Phase II/III Clinical Trial to Assess Immunogenicity and Safety of EG-MCV4 Meningococcal (Groups A, C, W-135, and Y) Conjugated Vaccines
Latest Information Update: 08 Dec 2025
At a glance
- Drugs EG MCV4 (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
- Indications Meningococcal infections
- Focus Pharmacodynamics
- Sponsors EyeGene
Most Recent Events
- 21 Nov 2025 Status changed from not yet recruiting to recruiting.
- 16 Oct 2025 New trial record